ALXN - Alexion Pharmaceuticals, Inc.
| Previous Close | 131.40 |
| Open | 130.60 |
| Bid | 131.18 x 1100 |
| Ask | 134.35 x 900 |
| Day's Range | 129.87 - 131.97 |
| 52 Week Range | 92.56 - 141.86 |
| Volume | 943,754 |
| Avg. Volume | 1,327,942 |
| Market Cap | 29.353B |
| Beta (3Y Monthly) | 1.70 |
| PE Ratio (TTM) | 70.30 |
| EPS (TTM) | 1.86 |
| Earnings Date | Jul 24, 2019 - Jul 29, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 163.28 |
- Zacks•3 days ago
ALXN or ALKS: Which Is the Better Value Stock Right Now?
ALXN vs. ALKS: Which Stock Is the Better Value Option?
- Business Wire•5 days ago
Alexion to Present at the RBC Capital Markets Annual Healthcare Conference
Alexion Pharmaceuticals today announced that management will present at the RBC Capital Markets Annual Healthcare Conference in New York, NY on Tuesday, May 21, 2019 at 9:30 a.m.
- Business Wire•5 days ago
Alexion to Present at the UBS Global Healthcare Conference
Alexion Pharmaceuticals today announced that management will present at the UBS Global Healthcare Conference in New York, NY on Monday, May 20, 2019 at 11:30 a.m. ET.
- Zacks•6 days ago
Achillion (ACHN) Reports Wider-Than-Expected Loss in Q1
Achillion (ACHN) reports narrower year-over-year loss in Q1. The absence of an approved product results in no revenues in the quarter.
- Insider Monkey•6 days ago
Alexion Pharmaceuticals, Inc. (ALXN): Sound Shore Says the Pharmaceutical Company is Driving Innovation
Sound Shore posted 20 year annualized returns of 7.30% and 7.51% for its Sound Shore Fund Investor Class (SSHFX) and Institutional Class (SSHVX), respectively, in its Q1 2019 Investor Letter. You can download a copy of the letter here. The figures go to show that the fund outperformed both the Russel Value and the S&P […]
- Zacks•10 days ago
What Makes Alexion (ALXN) a New Buy Stock
Alexion (ALXN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank 2 (Buy).
- Zacks•11 days ago
Biotech ETFs in Focus on String of Q1 Earnings Beats
Let's take a sneak peek at some ETFs having high exposure to some impactful biotechnological companies on the release of Q1 earnings results.
- Markit•12 days ago
See what the IHS Markit Score report has to say about Alexion Pharmaceuticals Inc.
Alexion Pharmaceuticals Inc NASDAQ/NGS:ALXNView full report here! Summary * ETFs holding this stock have seen outflows over the last one-month * Bearish sentiment is low * Economic output in this company's sector is expanding Bearish sentimentShort interest | PositiveShort interest is extremely low for ALXN with fewer than 1% of shares on loan. This could indicate that investors who seek to profit from falling equity prices are not currently targeting ALXN. Money flowETF/Index ownership | NegativeETF activity is negative. Over the last one-month, outflows of investor capital in ETFs holding ALXN totaled $3.38 billion. Additionally, the rate of outflows appears to be accelerating. Economic sentimentPMI by IHS Markit | PositiveAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is strong relative to the trend shown over the past year, and is accelerating. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to score@ihsmarkit.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
- Business Wire•16 days ago
New England Journal of Medicine Publishes Positive Phase 3 PREVENT Data for SOLIRIS® (eculizumab) in Patients with Neuromyelitis Optica Spectrum Disorder (NMOSD)
Alexion Pharmaceuticals, Inc. (ALXN) today announced that the New England Journal of Medicine (NEJM) published positive data from the Phase 3 PREVENT study of SOLIRIS® (eculizumab), a first-in-class complement inhibitor, in adult patients with anti-aquaporin-4 (AQP4) auto antibody-positive neuromyelitis optica spectrum disorder (NMOSD).
GuruFocus.com•16 days agoEaton Vance Worldwide Health Sciences Fund Buys 5 New Stocks
Fund releases 1st-quarter portfolio
- Zacks•17 days ago
The Zacks Analyst Blog Highlights: Biogen, Celgene, Incyte, Alexion and Vertex
The Zacks Analyst Blog Highlights: Biogen, Celgene, Incyte, Alexion and Vertex
- Zacks•18 days ago
Biotech Stock Roundup: BIIB, VRTX, ALXN Q1 Earnings Top & Other Pipeline Updates
Key highlights of the past week are earnings releases by most leading biotech entities.
- Zacks•18 days ago
Is Alexion (ALXN) a Solid Growth Stock? 3 Reasons to Think " Yes "
Alexion (ALXN) is well positioned to outperform the market, as it exhibits above-average growth in financials.
- Investopedia•18 days ago
Top Biotech Stocks for February 2019
Biotech a thrilling industry for investors, and one with tremendous opportunity for gains, as shown in early 2019, but it is notably risky for investors, too.
- Thomson Reuters StreetEvents•22 days ago
Edited Transcript of ALXN earnings conference call or presentation 25-Apr-19 12:00pm GMT
Q1 2019 Alexion Pharmaceuticals Inc Earnings Call
- Business Wire•23 days ago
Alexion Receives Positive CHMP Opinion for ULTOMIRIS® (ravulizumab) in Adults with Paroxysmal Nocturnal Hemoglobinuria (PNH)
Alexion Pharmaceuticals, Inc. (ALXN) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion, recommending marketing authorization for ULTOMIRIS® (ravulizumab), the first and only long-acting C5 complement inhibitor administered every eight weeks. The recommended indication is for the treatment of adult patients with paroxysmal nocturnal haemoglobinuria (PNH) with haemolysis with clinical symptoms indicative of high disease activity,1 and also for adult patients who are clinically stable2 after having been treated with SOLIRIS® (eculizumab) for at least the past six months.
- Investor's Business Daily•23 days ago
This Biotech's Newest Drug Could Own The Market In Just 5 Quarters
Alexion Pharmaceuticals beat first-quarter expectations Thursday and raised its 2019 outlook, but sales of treatments for metabolic diseases floundered and continue to be a "sore point."
Motley Fool•23 days agoAlexion Pharmaceuticals Inc (ALXN) Q1 2019 Earnings Call Transcript
ALXN earnings call for the period ending March 31, 2019.
- Motley Fool•24 days ago
Alexion Pharmaceuticals Fires on All Cylinders in Q1
The biotech posts strong sales growth for all of its rare-disease drugs in the first quarter.
- Zacks•24 days ago
Alexion (ALXN) Q1 Earnings Beat Estimates, Guidance Raised
Alexion (ALXN) beats earnings and sales estimates in the first quarter of 2019 and raises guidance for the year.
- Zacks•24 days ago
Alexion (ALXN) Tops Q1 Earnings and Revenues Beat Estimates
Alexion (ALXN) beats both earnings and sales estimates in the first quarter of 2019.
- Simply Wall St.•24 days ago
Has Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) Got Enough Cash?
With a market capitalization of US$30b, Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) is a large-cap stock, which is considered by most investors as a safe bet. Common characteristics for these big stocks are their strong balance sheet...
- MarketWatch•24 days ago
You can find plenty of solid stock bargains in this year’s worst-performing sector, analysts say
Health-care stocks are being dragged down by fears that a remake of the U.S. health-care system would stunt profits.
- Associated Press•24 days ago
Alexion: 1Q Earnings Snapshot
On a per-share basis, the Boston-based company said it had profit of $2.61. Earnings, adjusted for one-time gains and costs, came to $2.39 per share. The results beat Wall Street expectations. The average ...
